Does PSA screening reduce prostate cancer mortality?

Vis, Andre N.
March 2002
CMAJ: Canadian Medical Association Journal;3/5/2002, Vol. 166 Issue 5, p600
Academic Journal
Comments on the controversial issue of prostate-specific antigen (PSA) screening for prostate cancer. Data on and possible explanations for the decline in the prostate cancer mortality rate in the U.S.; Reference to a study by the urology department of the University of Innsbruck, Austria that indicated a beneficial effect of prostate cancer screening; Criticism of the PSA screening study by Perron et al in Quebec; View that more screening trials are needed.


Related Articles

  • Europeans collaborate screening trials for prostate cancer. Reynolds, Tom // JNCI: Journal of the National Cancer Institute;6/21/95, Vol. 87 Issue 12, p868 

    Reports that European health authorities are supporting trials that they hope will answer crucial questions about the efficacy of prostate-specific antigen (PSA) testing as a screening tool before it becomes an established but unproven practice in their countries. Operating procedures of the...

  • Total PSA predicts prostate cancer better then free/total PSA ratio.  // Geriatrics;Oct2001, Vol. 56 Issue 10, p46 

    Presents an abstract of the study `Serial Prostate Specific Antigen, Free-to-total Prostate Specific Antigen Ratio and Complexed Prostate Specific Antigen for the Diagnosis of Prostate Cancer,' by W.J. Ellis, R. Etzioni et al., from the July 2001 issue of the `Journal of Urology.'

  • Total PSA values of 3 to 10 ng/ml merit calculation of `percent free PSA'.  // Modern Medicine;Aug96, Vol. 64 Issue 8, p9 

    Reports that calculating the percentage of free prostate-specific antigen (PSA) in men whose total PSA levels are between 3 and 10 ng/ml can help reduce a number of unnecessary biopsies. Ability of the percent free PSA in these men to accurately distinguish between a high risk of prostate...

  • Using the Free-to-total Prostate-specific Antigen Ration to Detect Prostate Cancer in Men with... Hoffman, Richard M.; Clanon, David L.; Littenberg, Benjamin; Frank, Joseph J.; Peirce, John C. // JGIM: Journal of General Internal Medicine;Oct2000, Vol. 15 Issue 10, p739 

    BACKGROUND: Prostate-specific antigen (PSA) levels between 4.0 to 10.0 ng/ml have poor specificity in prostate cancer screening, leading to unnecessary biopsies. OBJECTIVE: To determine whether the free-to-total PSA ratio (F/T PSA) improved the diagnostic accuracy of these nonspecific PSA...

  • Early Detection and Aggressive Treatment of Prostate Cancer. Barry, Michael J. // JGIM: Journal of General Internal Medicine;Oct2000, Vol. 15 Issue 10, p749 

    The diffusion of early detection of prostate cancer with the prostate-specific antigen (PSA) test and subsequent aggressive treatment for the cancers discovered, in the absence of randomized trials documenting such screening efforts do more good than harm, has been nothing short of remarkable in...

  • What you can learn from percent free PSA testing. Potter, Steven R.; Partin, Alan W. // Patient Care;3/15/2000, Vol. 34 Issue 5, p94 

    Explains when to use percent free prostate specific antigen (PSA) testing and how to interpret the information it provides. Usefulness of PSA for detecting prostate cancer; Limitation of PSA by the lack of specificity within a diagnostic gray zone; Advantages offered by percent free PSA over...

  • PSA as a Treatment Marker for Prostate Cancer? Miller, Mike // JNCI: Journal of the National Cancer Institute;07/07/99, Vol. 91 Issue 13, p1108 

    Deals with the results of a study which evaluated the effectivity of prostatic specific antigen (PSA) as a diagnostic tool and treatment for prostate cancer. How the study was conducted; Comments from Nicholas James from the University of Birmingham in England.

  • Preferences of Elderly Men for Prostate-Specific Antigen Screening and the Impact of Informed... Wolf, Andrew M. D.; Schorling, John B. // Journals of Gerontology Series A: Biological Sciences & Medical ;May98, Vol. 53A Issue 3, pM195 

    Focuses on a study which determined the efficacy and preferences of old men for prostate-specific antigen (PSA), an screening test for prostate cancer. Methodology; Predictors of interest in PSA screening; Bivariate predictors of interest in PSA screening; Conclusion.

  • Complexed PSA cuts rate of false positives by 25%. Bankhead, Charles // Urology Times;May99, Vol. 27 Issue 5, p1 

    Reports on the findings of physician Michael Brawer about the benefits of measuring complexed prostate specific antigen (PSA) in improving the diagnosis of prostate cancer. Generation of more accurate findings; Cost reduction due to elimination of multiple tests; Empirical findings supporting...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics